免疫沉澱市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、類型、最終用途、地區和競爭格局分類，2021-2031年

全球免疫沉澱市場預計將從 2025 年的 7.2144 億美元成長到 2031 年的 10.1071 億美元，複合年成長率為 5.78%。

這種特殊的親和性和純化技術利用特異性抗體從異質生物樣本分離目標蛋白或複合物。該市場的成長主要得益於基因組學和蛋白​​質組學研究的日益普及，這些研究需要在藥物發現和開發過程中進行精確的蛋白質相互作用分析。生命科學領域的大量資本投資也支撐了這一成長趨勢，使得這些生物分析工具得以廣泛應用。例如，歐洲製藥工業協會聯合會（EFPIA）估計，到2024年，歐洲以研發為基礎的製藥業將在研發方面投入550億歐元，這凸顯了巨額投資對先進實驗技術需求的推動作用。

儘管資金籌措環境有利，但抗體特異性和交叉反應性問題仍是阻礙市場擴張的主要挑戰。這常常導致實驗結果出現差異。由於該技術高度依賴高品質、檢驗的抗體，試劑性能的不一致性會導致假陽性結果。因此，實驗室不得不投入大量資金來檢驗流程，從而限制了該技術在高通量工業應用中的擴充性。

市場促進因素

慢性病和自體免疫疾病發生率的上升是推動免疫沉澱技術應用的主要動力。這些疾病需要進行嚴謹的蛋白質體學分析以有效鑑定生物標記。隨著癌症等複雜疾病的日益普遍，精確分離抗原以闡明蛋白質-蛋白質相互作用對於標靶治療的開發至關重要。疾病負擔統計數據也從數量上印證了這項需求。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》，預計2024年美國將新增2,001,140例癌症病例。因此，臨床實驗室越來越依賴親和性和純化方法來闡明這些疾病的分子機制，導致免疫沉澱試劑和試劑盒的持續消耗。

除了臨床需求外，製藥和生技公司不斷增加的研發投入也為採用自動化、高通量免疫沉澱系統提供了必要的資金。高額的企業投資使得公司能夠採購檢驗的抗體和先進的磁珠，這對於降低藥物研發流程中的實驗變異至關重要。例如，默克公司在2024年2月發布的2023會計年度年度報告中指出，其2023會計年度的研發總支出達到305億美元。除了私部門的支出外，公共部門通常會採取措施加強基礎建設。英國政府在2024年宣布了一項4億英鎊的投資計劃，旨在進一步促進這些生物分析工具的資源取得。

市場挑戰

全球免疫沉澱市場面臨的主要挑戰是抗體特異性和交叉反應性這一長期存在的問題。當抗體與目標抗原以外的非預期蛋白結合時，就會出現假陽性結果和實驗噪聲，嚴重影響數據的可靠性。這種不確定性導致實驗室需要進行嚴格且耗時的檢驗程序，從而擾亂工作流程並顯著增加營運成本。因此，研究機構難以證明這種需要如此廣泛檢驗才能確保準確性的方法具有擴充性，從而限制了其在時間緊迫、高通量工業環境中的應用。

這種可靠性差距正在那些需要精確分子表徵的領域造成嚴重的瓶頸。目前正在進行的大量研究凸顯了市場機會面臨的風險。根據美國製藥商協會（PhRMA）預測，到2024年，將有超過8000種藥物處於臨床開發階段，這意味著龐大的研發管線需要精確的蛋白質分析。由於擔心交叉反應試劑會損害這些高價值藥物資產的數據完整性，各機構被迫減少對免疫沉澱分析法的依賴，這直接阻礙了該技術向廣泛商業性應用領域的拓展。

市場趨勢

人工智慧和機器學習在數據分析領域的應用，正從根本上改變全球免疫沉澱市場，有效應對了高維度蛋白質體學資料集的複雜性。由於免疫沉澱分析法通常會產生大量數據，尤其是在與質譜聯用時，實驗室正採用機器學習演算法來區分真正的蛋白質相互作用和背景噪聲，從而提高實驗的可重複性和效率。這種數位轉型正日益凸顯該技術在關鍵監管通路中的效用，藥物研發中對計算生物學的日益依賴便是明證。根據2024年11月《藥物發現趨勢》（Drug Discovery Trends）報導上題為「2024：人工智慧藥物發現和蛋白質結構預測元年」的文章，2016年至2023年間，美國食品藥品監督管理局（FDA）收到了超過500份包含人工智慧元素的上游工程申請，這表明依賴人工智慧流程已被廣泛接受的整合式人工智慧元素整合。

同時，次世代定序與ChIP-Seq工作流程的整合，正以前所未有的解析度實現全基因組蛋白質-DNA交互作用圖譜的繪製，從而革新表觀遺傳學研究。這一趨勢代表著對傳統微陣列方法的重大技術進步，研究人員擴大將染色質免疫沉澱分析法與定序平台結合，以識別對理解基因調控至關重要的轉錄因子結合位點和組蛋白修飾。定序服務提供者完善的基礎設施為該方法的擴充性提供了支持，促進了其在學術界和商業領域的廣泛應用。根據Illumina公司於2024年2月發布的2023會計年度財報，該公司營收達到45億美元，凸顯了龐大的商業生態系統的存在，該生態系統為現代ChIP-Seq應用所必需的定序技術提供了支撐。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球免疫沉澱市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（試劑盒、試劑（抗體、磁珠等））
  • 依類型（單一蛋白質、蛋白質複合物、染色質、核糖核蛋白、標記蛋白質）
  • 透過申請（學術和研究機構、製藥和生物技術公司等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美免疫沉澱市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲免疫沉澱市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區免疫沉澱市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲免疫沉澱市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲免疫沉澱市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球免疫沉澱市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Abcam Limited
• GenScript Biotech Corporation
• Merck KGaA
• Bio-Rad Laboratories Inc.
• Takara Bio Inc.
• BioLegend, Inc.
• ROCKLAND IMMUNOCHEMICALS, Inc.
• Abbkine, Inc.
• Cell Signaling Technology, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Immunoprecipitation Market is projected to expand from USD 721.44 Million in 2025 to USD 1010.71 Million by 2031, registering a CAGR of 5.78%. This specialized affinity purification technique employs specific antibodies to isolate targeted proteins or complexes from heterogeneous biological samples. The market is primarily driven by an intensified focus on genomic and proteomic research, which necessitates precise protein interaction analysis for drug discovery and development. This growth trajectory is supported by substantial capital investments in the life sciences sector, enabling the extensive adoption of these bio-analytical tools. For instance, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested €55,000 million in R&D within Europe in 2024, highlighting the massive financial commitment fueling the demand for advanced laboratory techniques.

Despite this favorable funding environment, a significant challenge impeding market expansion is the issue of antibody specificity and cross-reactivity, which frequently leads to experimental variability. Because the technique relies heavily on high-quality, validated antibodies, any inconsistency in reagent performance can result in false positives. This forces laboratories to invest heavily in validation processes, thereby limiting the technique's scalability for high-throughput industrial applications.

Market Driver

The escalating incidence of chronic diseases and autoimmune disorders acts as a primary catalyst for the adoption of immunoprecipitation techniques, as these pathologies require rigorous proteomic analysis for effective biomarker identification. As the prevalence of complex conditions such as cancer rises, the need for precise antigen isolation to map protein-protein interactions becomes critical for developing targeted therapeutics. This demand is quantitatively supported by disease burden statistics; according to the American Cancer Society's 'Cancer Facts & Figures 2024' released in January 2024, it is projected that 2,001,140 new cancer cases will occur in the United States in 2024. Consequently, clinical research laboratories are increasingly dependent on affinity purification methods to dissect the molecular mechanisms of these diseases, sustaining the consumption of immunoprecipitation reagents and kits.

Parallel to clinical demand, the intensification of research and development expenditures by pharmaceutical and biotechnology firms provides the necessary capital to integrate automated and high-throughput immunoprecipitation systems. High-level corporate investment allows for the procurement of validated antibodies and advanced beads, which are essential for reducing experimental variability in drug discovery pipelines. For example, Merck & Co., Inc. reported in its February 2024 '2023 Annual Report' that total research and development expenses reached $30.5 billion for the fiscal year 2023. This private sector spending is often complemented by public initiatives to strengthen infrastructure; the UK Government announced a £400 million investment package in 2024 to bolster the nation's life sciences sector, further ensuring the availability of resources for utilizing such bio-analytical tools.

Market Challenge

The primary challenge hindering the Global Immunoprecipitation Market is the persistent issue of antibody specificity and cross-reactivity. When antibodies bind to unintended proteins alongside the target antigen, it generates false positive results and experimental noise, severely undermining data reliability. This uncertainty compels laboratories to implement rigorous, time-consuming validation steps, which disrupt workflows and significantly increase operational costs. Consequently, the technique's adoption in time-sensitive, high-throughput industrial settings is restricted, as research organizations struggle to justify the scalability of a method that requires such extensive verification to ensure accuracy.

This reliability gap creates a substantial bottleneck in a sector driven by the need for precise molecular characterization. The magnitude of the market opportunity currently at risk is highlighted by the massive volume of ongoing research. According to the Pharmaceutical Research and Manufacturers of America, in 2024, there were more than 8,000 medicines in clinical development, representing a vast pipeline that necessitates flawless protein analysis. The apprehension that cross-reactive reagents could compromise the integrity of data for these high-value assets leads organizations to limit their reliance on immunoprecipitation, thereby directly hampering the market's expansion into broader commercial applications.

Market Trends

The Incorporation of AI and Machine Learning in Data Analysis is fundamentally reshaping the Global Immunoprecipitation Market by addressing the complexity of high-dimensional proteomic datasets. As immunoprecipitation frequently generates vast amounts of data, particularly when coupled with mass spectrometry, laboratories are deploying machine learning algorithms to distinguish true protein interactions from background noise, thereby enhancing experimental reproducibility and efficiency. This digital transformation is increasingly validating the technique's utility in critical regulatory pathways, as evidenced by the growing reliance on computational biology in therapeutic development. According to Drug Discovery Trends, November 2024, in the article '2024: The year AI drug discovery and protein structure prediction took center stage', there have been more than 500 FDA submissions with AI components from 2016 to 2023, signaling a robust acceptance of AI-integrated workflows that rely on precise upstream protein isolation.

Simultaneously, the Integration of Next-Generation Sequencing in ChIP-Seq Workflows is revolutionizing epigenetic research by enabling genome-wide mapping of protein-DNA interactions with unprecedented resolution. This trend represents a technical evolution from traditional microarray-based methods, as researchers increasingly combine chromatin immunoprecipitation with sequencing platforms to identify transcription factor binding sites and histone modifications essential for understanding gene regulation. The scalability of this approach is underpinned by the established infrastructure of sequencing providers, which facilitates widespread adoption across academic and commercial sectors. According to Illumina, February 2024, in the 'Fiscal Year 2023 Financial Results', the company reported total revenue of $4.50 billion, highlighting the massive commercial ecosystem supporting the sequencing technologies that are integral to modern ChIP-Seq applications.

Key Market Players

• Thermo Fisher Scientific Inc.
• Abcam Limited
• GenScript Biotech Corporation
• Merck KGaA
• Bio-Rad Laboratories Inc.
• Takara Bio Inc.
• BioLegend, Inc.
• ROCKLAND IMMUNOCHEMICALS, Inc.
• Abbkine, Inc.
• Cell Signaling Technology, Inc.

Report Scope

In this report, the Global Immunoprecipitation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoprecipitation Market, By Product

• Kits
• Reagents (Antibodies, Beads, Others)

Immunoprecipitation Market, By Type

• Individual Protein
• Protein Complex
• Chromatin
• Ribonucleo Protein
• Tagged Proteins

Immunoprecipitation Market, By End-use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Immunoprecipitation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoprecipitation Market.

Available Customizations:

Global Immunoprecipitation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoprecipitation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits, Reagents (Antibodies, Beads, Others))
  • 5.2.2. By Type (Individual Protein, Protein Complex, Chromatin, Ribonucleo Protein, Tagged Proteins)
  • 5.2.3. By End-use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Immunoprecipitation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoprecipitation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Immunoprecipitation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Immunoprecipitation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-use

7. Europe Immunoprecipitation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoprecipitation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Immunoprecipitation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Immunoprecipitation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Immunoprecipitation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Immunoprecipitation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-use

8. Asia Pacific Immunoprecipitation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunoprecipitation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Immunoprecipitation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Immunoprecipitation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Immunoprecipitation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Immunoprecipitation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Immunoprecipitation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunoprecipitation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Immunoprecipitation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Immunoprecipitation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-use

10. South America Immunoprecipitation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Type
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunoprecipitation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Immunoprecipitation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Immunoprecipitation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunoprecipitation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abcam Limited
• 15.3. GenScript Biotech Corporation
• 15.4. Merck KGaA
• 15.5. Bio-Rad Laboratories Inc.
• 15.6. Takara Bio Inc.
• 15.7. BioLegend, Inc.
• 15.8. ROCKLAND IMMUNOCHEMICALS, Inc.
• 15.9. Abbkine, Inc.
• 15.10. Cell Signaling Technology, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer